Vitiligo

Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.

Rocco Serrao, MD, FAAD, a board-certified dermatologist, discusses a case of vitiligo involving a 20-year-old male patient who presents with white patches on his face that have persisted for 6 weeks without any relevant chemical exposures, and emphasizes the importance of providing counseling and support to address the potential impact on the patient's self-esteem and confidence.

The primary efficacy endpoint is the proportion of subjects achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index.

These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.

VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.

VYNE expects to enroll the first patient with vitiligo in the phase 2b trial for VYN201 in the second quarter of 2024.

Topical Bacitracin, Neosporin, and Vaseline were applied to mice over a 6-week period.

In addition, authors of a research letter noted that patients with vitiligo demonstrated a comparable risk of myocardial infarction and cerebrovascular accident.

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

Combining fire needle therapy with a 308 nm excimer laser for vitiligo treatment, as per a recent meta-analysis, was deemed both safe and effective.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

While the addition of NAC yielded greater improvement than microneedling alone, this difference was not significant.

A recent study aimed to investigate the risk of myocardial infarction, cerebrovascular accident, peripheral vascular disease, and pulmonary embolism in patients with vitiligo.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

The study uncovered sexual dimorphism in melanocyte stem cell migration rates due to UVB-induced inflammatory responses in mice.

The recommendations were recently published in JAMA Dermatology following an extensive literature review, article grading, and a review of research questions.

While additional, larger studies are necessary, researchers said dietary choices may help reduce dependency on pharmacological methods.

The social and psychological effects of vitiligo, particularly concerning gender disparities, have come to the forefront in recent literature.

Several posters presented at the American Academy of Dermatology Annual Meeting explored the topic of skin tone bias related to vitiligo in Google and internet search platforms.

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

Maggi Ahmed, MD, PhD, demonstrated superior pigmentation outcomes and reduced CD8+ T cell numbers in her recent research results.

Dive into a complex case report of a 29-year-old African American male patient with Fitzpatrick skin type V with a 6-month reported history of vitiligo on his lips.

The combination therapy did not yield any effect in patients with non-segmental vitiligo and prompts additional large studies prior to conclusive efficacy.

Researchers noted that this study's findings are consistent with prior epidemiologic data.

For a patient with vitiligo who is concerned about potential flares, what might you recommend avoiding?